Enterprise Value

70.72M

Cash

114.3M

Avg Qtr Burn

-21.96M

Short % of Float

13.01%

Insider Ownership

14.37%

Institutional Own.

65.33%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korsuva IV (CR845 IV) Details
Pruritus with chronic kidney disease , Kidney disease

Approved

Quarterly sales

Oral Korsuva (CR845) Details
Pruritus CKD (Chronic Kidney Disease) Stages 3 - 5

Phase 3

Data readout

Oral Korsuva (CR845) Details
Skin disease/disorder, Inflammatory disease, Atopic dermatitis, Atopic pruritus

Phase 3

Interim Update

Oral Korsuva (CR845) Details
Chronic pruritus, Pruritus associated with notalgia paresthetica

Phase 2

Update

Oral Korsuva (CR845) Details
Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder

Failed

Discontinued